ClinicalTrials.gg
CompletedNCT05412004SURMOUNT-OSAUpdated Apr 30, 2025Results posted

Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

A Phase 3 interventional study of Tirzepatide and Placebo in Obstructive Sleep Apnea and Obesity, sponsored by Eli Lilly and Company. Completed at 58 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-30.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
469
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 753 studies in Sleep Apnea, Obstructive with a site in United States — 126 open to participants now, 160 under way, 9 of them phase 3. Sleep Apnea, Obstructive · United States.

Enrollment
32nd of 594
469 · median 49
Started
2022
with 39 others
Phase 3
39 of 753
6 open now
Registered
581st of 753
by date

Among the 753 studies in Sleep Apnea, Obstructive with a site in United States, this one is the 32nd largest by enrollment of the 594 interventional ones that give a count, is one of 40 that started in 2022, is one of 39 in phase 3, and was the 581st registered.

Sleep Apnea, Obstructive

2,243 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

126 of the 753 studies in Sleep Apnea, Obstructive with a site in United States are open now. Recruiting first, the newest first:

121 more — sign in →

All 126 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 313 Sleep Apnea, Obstructive studies recruiting now, 146 (47%) set no upper age limit and 124 (40%) stop at 75 or younger; 52 take children under 18; 65 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 753 studies in Sleep Apnea, Obstructive with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect and safety of tirzepatide in participants with moderate to severe obstructive sleep apnea and obesity who are both unwilling or unable to use Positive Airway Pressure (PAP) therapy in GPI1 and those who are and plan to stay on PAP therapy in GPI2.

03

Conditions studied

  • Obstructive Sleep Apnea
  • Obesity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For GPI1 Participants:

  • Participants who are unable or unwilling to use PAP therapy. Participants must not have used PAP for at least 4 weeks prior to screening.

For GPI2 Participants:

  • Have been on PAP therapy for at least 3 consecutive months prior to screening and plan to continue PAP therapy during the study

For Both GPI1 and GPI2 Participants:

  • Have an AHI ≥15 on PSG as part of the trial at screening
  • Have a (BMI) ≥30 kilogram/square meter (kg/m²)
  • Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight

Exclusion criteria

Exclusion Criteria:

For GPI2 Participants:

  • Have personal or job-related responsibilities, or in the opinion of the investigator have any situation, that would make it unsafe to stop PAP therapy for 7 days prior to PSG testing during the course of the study
  • Are unwilling to stop PAP therapy for 7 days prior to polysomnography (PSG) testing during the course of the study

For GPI1 and GPI2 Participants:

  • Female participants must not be pregnant, intending to be pregnant, breastfeeding, or intending to breastfeed.
  • Have type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM), history of ketoacidosis, or hyperosmolar state/coma.
  • Have ≥ 6.5% (≥ 48 mmol/mol) at baseline
  • Any previous or planned surgery for sleep apnea or major ear, nose or throat surgery, including tonsillectomy and adenoidectomy that still may affect breathing at time of baseline
  • Have significant craniofacial abnormalities that may affect breathing at baseline
  • Have diagnosis of Central or Mixed Sleep Apnea with % of mixed or central apneas/hypopneas ≥50%, or diagnosis of Cheyne Stokes Respiration
  • Diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia.
  • Active device treatment of OSA other than PAP therapy (for example, dental appliance), or other treatment, that in the opinion of the investigator, may interfere with study outcomes, unless willing to stop treatment at baseline and throughout the study.
  • Respiratory and neuromuscular diseases that could interfere with the results of the trial in the opinion of the investigator.
  • Have a self-reported change in body weight >5 kg within 3 months prior to screening
  • Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty if performed more than 1 year prior to screening)
  • Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months (for example, mucosal ablation, gastric artery embolization, intragastric balloon, and duodenal-jejunal bypass sleeve)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
469 participants (actual)

Study arms

  • Experimental
    Tirzepatide MTD_GPI1

    Participants not on positive airway pressure (PAP) therapy received a maximum tolerated dose (MTD) of 10 milligrams (mg) or 15 mg of Tirzepatide once weekly (QW) as a subcutaneous (SC) injection for 52 weeks, including the initial dose escalation by 2.5 mg every 4 weeks

    Drug: Tirzepatide

  • Placebo comparator
    Placebo_GPI1

    Participants not on PAP therapy received placebo QW as an SC injection for 52 weeks.

    Drug: Placebo

  • Experimental
    Tirzepatide MTD_GPI2

    Participants who are on PAP therapy received an MTD of 10 mg or 15 mg of Tirzepatide QW as an SC injection for 52 weeks, including the initial dose escalation by 2.5 mg every 4 weeks

    Drug: Tirzepatide

  • Placebo comparator
    Placebo_GPI2

    Participants who are on PAP therapy received placebo QW as an SC injection for 52 weeks.

    Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY3298176

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Apnea-Hypopnea Index (AHI)

    AHI, Apnea-Hypopnea Index, is the number of apneas or hypopneas recorded via polysomnography during the study per hour of sleep. Apnea is defined as a cessation of airflow lasting at least 10 seconds, hypopnea as a decrease in airflow by at least 30% from baseline for at least 10 seconds occurring with a drop in oxygen saturation (SpO₂) by at least 4%. AHI values are categorized as 5-15 events/hr = mild; 15-\<30 events/hr = moderate; and ≥ 30 events/hr = severe. a significant reduction in values indicates a positive outcome.

    Time frame: Baseline, Week 52

Secondary outcomes

  1. Percent Change From Baseline in Apnea-Hypopnea Index (AHI)

    Percent Change From Baseline in AHI was evaluated.

    Time frame: Baseline, Week 52

  2. Percentage of Participants With ≥50% AHI Reduction From Baseline

    Percentage of participants achieving ≥50% AHI reduction from baseline to Week 52 was evaluated.

    Time frame: Week 52

  3. Percentage of Participants With AHI <5 or With AHI 5-14 With Epworth Sleepiness Scale (ESS) ≤10

    The percentage of participants with OSA remission (AHI \<5 events per hour of sleep) or with mild OSA without excessive daytime sleepiness (AHI 5-14 events per hour of sleep with ESS ≤10) at Week 52 was evaluated. The ESS is used to assess improvements in excessive daytime sleepiness from baseline to Week 52. The ESS is an 8-item, participant-completed measure that asks the participant to rate, on a scale of 0 (no chance of dozing) to 3 (high chance of dozing), their usual chances of dozing in 8 different daytime situations, with a recall period of "in recent times." The ESS total score is the sum of the 8-item scores and ranges from 0 to 24, with higher scores indicating greater daytime sleepiness.

    Time frame: Week 52

  4. Change From Baseline in Sleep Apnea-Specific Hypoxic Burden (SASHB) (% Min/Hour)

    SASHB was determined by measuring the respiratory event-associated area under the curve for oxygen desaturation from pre-event baseline and represents the cumulative burden of intermittent hypoxia caused by OSA-related sleep-disordered breathing at sleep.

    Time frame: Baseline, Week 52

  5. Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form Sleep-Related Impairment 8a (PROMIS SRI) and PROMIS Short Form Sleep Disturbance 8b (PROMIS SD)

    PROMIS SRI consists of 8 items that assess self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and perceived functional impairments associated with sleep problems. PROMIS SRI has a recall period of "in the past 7 days" and each item is rated on a 5-point scale from "not at all" to "very much." PROMIS SD consists of 8 items that assess self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. PROMIS SD has a recall period of "in the past 7 days" and each item is rated on a 5-point scale ranging from "not at all" to "very much," "never" to "always," or "very poor" to "very good." For both PROMIS SRI and PROMIS SD, item responses are used to generate T-scores which are standardized scores with a mean of 50 and a standard deviation of 10 (score range cannot be specified for T-scores). Higher T-scores indicate worse outcomes; more sleep-related impairment (PROMIS SRI) or more sleep disturbance (PROMIS SD).

    Time frame: Baseline, Week 52

  6. Percent Change From Baseline in Body Weight

    Percent Change from Baseline in Body Weight was evaluated.

    Time frame: Baseline, Week 52

  7. Change From Baseline in High Sensitivity C Reactive Protein (hsCRP) Concentration

    HsCRP is a marker for inflammation and was measured from blood samples to identify the presence of inflammation, to determine its severity, and to monitor response to treatment.

    Time frame: Baseline, Week 52

  8. Change From Baseline in Systolic Blood Pressure (SBP)

    Change in systolic blood pressure from baseline to Week 48 was evaluated.

    Time frame: Baseline, Week 48

07

Results

Posted Apr 30, 2025

Participant flow

NCT05412004 supports two pivotal studies: I8F-MC-GPI1 (GPI1; Study 1) and I8F-MC-GPI2 (GPI2; Study 2), conducted under the single master protocol I8F-MC-GPIF. The studies were conducted under a single overarching trial structure for operational efficiencies, but the study participants for both studies are different (GPI1 included participants who were unable or unwilling to use positive airway pressure (PAP) therapy, while GPI2 included those on PAP therapy).

Participant flow — Overall Study
MilestoneTirzepatide MTD_GPI1Placebo_GPI1Tirzepatide MTD_GPI2Placebo_GPI2
Started114120120115
Received at least one dose of study drug114120119114
Completed1018611389
Not completed1334726
Withdrew: Adverse event0215
Withdrew: Assigned treatment by mistake51025
Withdrew: Lost to follow-up3000
Withdrew: Patient could not travel to site0100
Withdrew: Physician decision0100
Withdrew: Pregnancy0100
Withdrew: Protocol violation1000
Withdrew: Withdrawal by subject419414
Withdrew: Screen failure0001
Withdrew: The participant quit treatment and study due to their schedule and the final v801 was done remotely0001

Outcome measures

PrimaryChange From Baseline in Apnea-Hypopnea Index (AHI)

AHI, Apnea-Hypopnea Index, is the number of apneas or hypopneas recorded via polysomnography during the study per hour of sleep. Apnea is defined as a cessation of airflow lasting at least 10 seconds, hypopnea as a decrease in airflow by at least 30% from baseline for at least 10 seconds occurring with a drop in oxygen saturation (SpO₂) by at least 4%. AHI values are categorized as 5-15 events/hr = mild; 15-\<30 events/hr = moderate; and ≥ 30 events/hr = severe. a significant reduction in values indicates a positive outcome.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · events per hour
Change From Baseline in Apnea-Hypopnea Index (AHI)
events per hourTirzepatide MTD_GPI1Placebo_GPI1Tirzepatide MTD_GPI2Placebo_GPI2
Change From Baseline in Apnea-Hypopnea Index (AHI)-25.25 ± 2.06-5.25 ± 2.11-29.27 ± 1.99-5.51 ± 2.21
Statistical analysis
  • Tirzepatide MTD_GPI1 vs Placebo_GPI1 · ANCOVA · p = <0.001 · Ls mean change difference: -20.01 · 95% CI -25.82 to -14.20ANCOVA model was used with baseline, geographic region, sex, treatment (Type III sum of squares) as covariates.
  • Tirzepatide MTD_GPI2 vs Placebo_GPI2 · ANCOVA · p = <0.001 · Ls mean change difference: -23.77 · 95% CI -29.61 to -17.93ANCOVA model was used with baseline, geographic region, sex, treatment (Type III sum of squares) as covariates.
SecondaryPercent Change From Baseline in Apnea-Hypopnea Index (AHI)

Percent Change From Baseline in AHI was evaluated.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · percentage change
Percent Change From Baseline in Apnea-Hypopnea Index (AHI)
percentage changeTirzepatide MTD_GPI1Placebo_GPI1Tirzepatide MTD_GPI2Placebo_GPI2
Percent Change From Baseline in Apnea-Hypopnea Index (AHI)-50.68 ± 5.90-3.03 ± 7.07-58.72 ± 5.28-2.50 ± 6.95
Statistical analysis
  • Tirzepatide MTD_GPI1 vs Placebo_GPI1 · ANCOVA · p = <0.001 · Ls mean change difference: -47.65 · 95% CI -65.76 to -29.55ANCOVA model was used with baseline, geographic region, sex, treatment (Type III sum of squares) as covariates.
  • Tirzepatide MTD_GPI2 vs Placebo_GPI2 · ANCOVA · p = <0.001 · Ls mean change difference: -56.21 · 95% CI -73.73 to -38.70ANCOVA model was used with baseline, geographic region, sex, treatment (Type III sum of squares) as covariates.
SecondaryPercentage of Participants With ≥50% AHI Reduction From Baseline

Percentage of participants achieving ≥50% AHI reduction from baseline to Week 52 was evaluated.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With ≥50% AHI Reduction From Baseline
percentage of participantsTirzepatide MTD_GPI1Placebo_GPI1Tirzepatide MTD_GPI2Placebo_GPI2
Percentage of Participants With ≥50% AHI Reduction From Baseline61.2218.9672.4023.25
Statistical analysis
  • Tirzepatide MTD_GPI1 vs Placebo_GPI1 · Regression, Logistic · p = <0.001 · Risk difference (rd): 42.77 · 95% CI 30.76 to 54.79
  • Tirzepatide MTD_GPI2 vs Placebo_GPI2 · Regression, Logistic · p = <0.001 · Risk difference (rd): 48.60 · 95% CI 36.55 to 60.65
SecondaryPercentage of Participants With AHI <5 or With AHI 5-14 With Epworth Sleepiness Scale (ESS) ≤10

The percentage of participants with OSA remission (AHI \<5 events per hour of sleep) or with mild OSA without excessive daytime sleepiness (AHI 5-14 events per hour of sleep with ESS ≤10) at Week 52 was evaluated. The ESS is used to assess improvements in excessive daytime sleepiness from baseline to Week 52. The ESS is an 8-item, participant-completed measure that asks the participant to rate, on a scale of 0 (no chance of dozing) to 3 (high chance of dozing), their usual chances of dozing in 8 different daytime situations, with a recall period of "in recent times." The ESS total score is the sum of the 8-item scores and ranges from 0 to 24, with higher scores indicating greater daytime sleepiness.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With AHI <5 or With AHI 5-14 With Epworth Sleepiness Scale (ESS) ≤10
percentage of participantsTirzepatide MTD_GPI1Placebo_GPI1Tirzepatide MTD_GPI2Placebo_GPI2
Percentage of Participants With AHI <5 or With AHI 5-14 With Epworth Sleepiness Scale (ESS) ≤1042.1715.8850.2414.33
Statistical analysis
  • Tirzepatide MTD_GPI1 vs Placebo_GPI1 · Regression, Logistic · p = <.001 · Risk difference (rd): 28.74 · 95% CI 18.27 to 39.22
  • Tirzepatide MTD_GPI2 vs Placebo_GPI2 · Regression, Logistic · p = <0.001 · Risk difference (rd): 33.22 · 95% CI 22.12 to 44.31
SecondaryChange From Baseline in Sleep Apnea-Specific Hypoxic Burden (SASHB) (% Min/Hour)

SASHB was determined by measuring the respiratory event-associated area under the curve for oxygen desaturation from pre-event baseline and represents the cumulative burden of intermittent hypoxia caused by OSA-related sleep-disordered breathing at sleep.

Time frame:
Baseline, Week 52
Reported as:
Geometric least squares mean · %.min/hr
Change From Baseline in Sleep Apnea-Specific Hypoxic Burden (SASHB) (% Min/Hour)
%.min/hrTirzepatide MTD_GPI1Placebo_GPI1Tirzepatide MTD_GPI2Placebo_GPI2
Change From Baseline in Sleep Apnea-Specific Hypoxic Burden (SASHB) (% Min/Hour)-95.19 ± 4.081-25.07 ± 9.804-102.98 ± 3.758-41.69 ± 11.313
Statistical analysis
  • Tirzepatide MTD_GPI1 vs Placebo_GPI1 · Median difference (net): -70.13 · 95% CI -90.94 to -49.31
  • Tirzepatide MTD_GPI2 vs Placebo_GPI2 · Median difference (net): -61.29 · 95% CI -84.66 to -37.93
SecondaryChange From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form Sleep-Related Impairment 8a (PROMIS SRI) and PROMIS Short Form Sleep Disturbance 8b (PROMIS SD)

PROMIS SRI consists of 8 items that assess self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and perceived functional impairments associated with sleep problems. PROMIS SRI has a recall period of "in the past 7 days" and each item is rated on a 5-point scale from "not at all" to "very much." PROMIS SD consists of 8 items that assess self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. PROMIS SD has a recall period of "in the past 7 days" and each item is rated on a 5-point scale ranging from "not at all" to "very much," "never" to "always," or "very poor" to "very good." For both PROMIS SRI and PROMIS SD, item responses are used to generate T-scores which are standardized scores with a mean of 50 and a standard deviation of 10 (score range cannot be specified for T-scores). Higher T-scores indicate worse outcomes; more sleep-related impairment (PROMIS SRI) or more sleep disturbance (PROMIS SD).

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · T score
Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form Sleep-Related Impairment 8a (PROMIS SRI) and PROMIS Short Form Sleep Disturbance 8b (PROMIS SD)
T scoreTirzepatide MTD_GPI1Placebo_GPI1Tirzepatide MTD_GPI2Placebo_GPI2
Sleep Disturbance-4.47 ± 0.69-2.44 ± 0.70-6.98 ± 0.82-3.08 ± 0.88
Sleep-Related Impairment-6.57 ± 0.83-3.13 ± 0.80-8.18 ± 0.95-3.91 ± 1.03
Statistical analysis
  • Tirzepatide MTD_GPI1 vs Placebo_GPI1 · ANCOVA · p = 0.037 · Ls mean change difference: -2.03 · 95% CI -3.95 to -0.12ANCOVA model was used with baseline, geographic region, sex, baseline OSA severity Group, treatment (Type III sum of squares) as covariates.
  • Tirzepatide MTD_GPI1 vs Placebo_GPI1 · ANCOVA · p = 0.003 · Ls mean change difference: -3.43 · 95% CI -5.69 to -1.17ANCOVA model was used with baseline, geographic region, sex, baseline OSA severity Group, treatment (Type III sum of squares) as covariates.
  • Tirzepatide MTD_GPI2 vs Placebo_GPI2 · ANCOVA · p = <0.001 · Ls mean change difference: -3.90 · 95% CI -6.21 to -1.58ANCOVA model was used with baseline, geographic region, sex, baseline OSA severity Group, treatment (Type III sum of squares) as covariates.
  • Tirzepatide MTD_GPI2 vs Placebo_GPI2 · ANCOVA · p = 0.002 · Ls mean change difference: -4.26 · 95% CI -6.97 to -1.56ANCOVA model was used with baseline, geographic region, sex, baseline OSA severity Group, treatment (Type III sum of squares) as covariates.
SecondaryPercent Change From Baseline in Body Weight

Percent Change from Baseline in Body Weight was evaluated.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Body Weight
Percent changeTirzepatide MTD_GPI1Placebo_GPI1Tirzepatide MTD_GPI2Placebo_GPI2
Percent Change From Baseline in Body Weight-17.65 ± 0.69-1.56 ± 0.68-19.62 ± 0.71-2.34 ± 0.74
Statistical analysis
  • Tirzepatide MTD_GPI1 vs Placebo_GPI1 · ANCOVA · p = <0.001 · Ls mean change difference: -16.09 · 95% CI -17.99 to -14.19ANCOVA model was used with baseline, geographic region, sex, baseline OSA severity Group, treatment (Type III sum of squares) as covariates.
  • Tirzepatide MTD_GPI2 vs Placebo_GPI2 · ANCOVA · p = <.001 · Ls mean change difference: -17.28 · 95% CI -19.29 to -15.28ANCOVA model was used with baseline, geographic region, sex, baseline OSA severity Group, treatment (Type III sum of squares) as covariates.
SecondaryChange From Baseline in High Sensitivity C Reactive Protein (hsCRP) Concentration

HsCRP is a marker for inflammation and was measured from blood samples to identify the presence of inflammation, to determine its severity, and to monitor response to treatment.

Time frame:
Baseline, Week 52
Reported as:
Geometric least squares mean · Milligram per liter (mg/L)
Change From Baseline in High Sensitivity C Reactive Protein (hsCRP) Concentration
Milligram per liter (mg/L)Tirzepatide MTD_GPI1Placebo_GPI1Tirzepatide MTD_GPI2Placebo_GPI2
Change From Baseline in High Sensitivity C Reactive Protein (hsCRP) Concentration-1.42 ± 0.151-0.70 ± 0.203-1.37 ± 0.130-0.33 ± 0.236
Statistical analysis
  • Tirzepatide MTD_GPI1 vs Placebo_GPI1 · ANCOVA · p = 0.752 (ANCOVA model was used with baseline, geographic region, sex, baseline OSA severity Group, treatment (Type III sum of squares) as covariates.) · Ls mean change difference: -0.71 · 95% CI -1.21 to -0.22
  • Tirzepatide MTD_GPI2 vs Placebo_GPI2 · ANCOVA · p = 0.350 (ANCOVA model was used with baseline, geographic region, sex, baseline OSA severity Group, treatment (Type III sum of squares) as covariates.) · Ls mean change difference: -1.04 · 95% CI -1.57 to -0.51
SecondaryChange From Baseline in Systolic Blood Pressure (SBP)

Change in systolic blood pressure from baseline to Week 48 was evaluated.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · Millimeters of mercury (mm Hg)
Change From Baseline in Systolic Blood Pressure (SBP)
Millimeters of mercury (mm Hg)Tirzepatide MTD_GPI1Placebo_GPI1Tirzepatide MTD_GPI2Placebo_GPI2
Change From Baseline in Systolic Blood Pressure (SBP)-9.46 ± 1.02-1.84 ± 1.03-7.64 ± 1.03-3.94 ± 1.18
Statistical analysis
  • Tirzepatide MTD_GPI1 vs Placebo_GPI1 · ANCOVA · p = <0.001 · Ls mean change difference: -7.62 · 95% CI -10.48 to -4.77ANCOVA model was used with baseline, geographic region, sex, baseline OSA severity Group, treatment (Type III sum of squares) as covariates.
  • Tirzepatide MTD_GPI2 vs Placebo_GPI2 · ANCOVA · p = 0.017 · Ls mean difference: -3.70 · 95% CI -6.75 to -0.65ANCOVA model was used with baseline, geographic region, sex, baseline OSA severity Group, treatment (Type III sum of squares) as covariates.

Adverse events

Collected over Baseline to Follow-up (Up To 56 Weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tirzepatide MTD_GPI10/114 (0%)9/114 (7.9%)91/114 (79.8%)
Placebo_GPI10/120 (0%)7/120 (5.8%)91/120 (75.8%)
Tirzepatide MTD_GPI20/119 (0%)7/119 (5.9%)98/119 (82.4%)
Placebo_GPI20/114 (0%)12/114 (10.5%)82/114 (71.9%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventTirzepatide MTD_GPI1Placebo_GPI1Tirzepatide MTD_GPI2Placebo_GPI2
Abnormal uterine bleedingReproductive system and breast disorders0/360/410/321/32
Suicide attemptPsychiatric disorders2/1140/1200/1190/114
Atrial fibrillationCardiac disorders0/1142/1201/1190/114
Prostate cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/780/790/871/82
Acute myocardial infarctionCardiac disorders0/1140/1200/1191/114
Coronary artery diseaseCardiac disorders0/1140/1200/1191/114
DiarrhoeaGastrointestinal disorders1/1140/1201/1190/114
CholelithiasisHepatobiliary disorders0/1141/1200/1191/114
AppendicitisInfections and infestations1/1140/1200/1190/114
Dengue feverInfections and infestations0/1140/1201/1191/114
Most frequent other events
Showing 10 of 361
Most frequent other events
EventTirzepatide MTD_GPI1Placebo_GPI1Tirzepatide MTD_GPI2Placebo_GPI2
DiarrhoeaGastrointestinal disorders30/11415/12026/11910/114
NauseaGastrointestinal disorders29/11412/12026/1196/114
VomitingGastrointestinal disorders20/1145/12011/1191/114
ConstipationGastrointestinal disorders18/1143/12018/1195/114
NasopharyngitisInfections and infestations3/1148/12015/11912/114
Covid-19Infections and infestations6/11410/1208/11911/114
DyspepsiaGastrointestinal disorders5/1142/12011/1191/114
EructationGastrointestinal disorders9/1140/12010/1191/114
Upper respiratory tract infectionInfections and infestations7/11410/1205/1198/114
Gastrooesophageal reflux diseaseGastrointestinal disorders9/1141/1206/1190/114

Baseline characteristics

All randomized participants.

Age, Customized
Age, Customized(Participants)Tirzepatide MTD_GPI1Placebo_GPI1Tirzepatide MTD_GPI2Placebo_GPI2Total
<50years63625445224
>=50years51586670245
Sex: Female, Male
Sex: Female, Male(Participants)Tirzepatide MTD_GPI1Placebo_GPI1Tirzepatide MTD_GPI2Placebo_GPI2Total
Female36413332142
Male78798783327
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tirzepatide MTD_GPI1Placebo_GPI1Tirzepatide MTD_GPI2Placebo_GPI2Total
Hispanic or Latino51473838174
Not Hispanic or Latino63698276290
Unknown or Not Reported04015
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tirzepatide MTD_GPI1Placebo_GPI1Tirzepatide MTD_GPI2Placebo_GPI2Total
American Indian or Alaska Native9910937
Asian2324171680
Native Hawaiian or Other Pacific Islander00000
Black or African American678324
White74808586325
More than one race20002
Unknown or Not Reported00011
Region of Enrollment
Region of Enrollment(Participants)Tirzepatide MTD_GPI1Placebo_GPI1Tirzepatide MTD_GPI2Placebo_GPI2Total
United States35364137149
China14144537
Japan347620
Taiwan544316
Brazil2425181784
Mexico2019141669
Australia1510925
Germany77161646
Czechia566623
Baseline apnea-hypopnea index (AHI)
Baseline apnea-hypopnea index (AHI)(events per hour)Tirzepatide MTD_GPI1Placebo_GPI1Tirzepatide MTD_GPI2Placebo_GPI2Total
Mean52.86 ± 30.5050.13 ± 31.4746.08 ± 22.3553.10 ± 30.2350.49 ± 28.98
08

Study locations

58 sites
  • Artemis Institute for Clinical Research
    Riverside, California 92503, United States
  • Teradan Clinical Trials, LLC
    Brandon, Florida 33511, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • Palm Beach Research Center
    West Palm Beach, Florida 33409, United States
  • NeuroTrials Research Inc
    Atlanta, Georgia 30328, United States
  • Rocky Mountain Clinical Research
    Idaho Falls, Idaho 83404, United States
  • Brengle Family Medicine
    Indianapolis, Indiana 46260, United States
  • Lillestol Research
    Fargo, North Dakota 58104, United States
  • NeuroScience Research Center
    Canton, Ohio 44718, United States
  • CTI-CRC
    Cincinnati, Ohio 45212, United States
  • Office 18
    Pittsburgh, Pennsylvania 15236, United States
  • Preferred Primary Care Physicians
    Uniontown, Pennsylvania 15401, United States
  • FutureSearch Trials of Neurology
    Austin, Texas 78731, United States
  • Gadolin Research
    Beaumont, Texas 77702, United States
  • Advanced Neuro Research Center - ANRC
    El Paso, Texas 79912, United States
  • Epic Medical Research
    Red Oak, Texas 75154, United States
  • Sleep Therapy Research Center
    San Antonio, Texas 78229, United States
  • Rainier Clinical Research Center
    Renton, Washington 98057, United States
  • Woolcock Institute of Medical Research
    Sydney, New South Wales 2037, Australia
  • Flinders University
    Bedford Park, South Australia 5042, Australia
  • Núcleo de Pesquisa Clínica do Rio Grande do Sul
    Porto Alegre, Rio Grande Do Sul 90430-001, Brazil
  • CPCLIN
    Sao Paulo, São Paulo 01228-200, Brazil
  • CPQuali Pesquisa Clínica
    São Paulo, 01228-000, Brazil
  • Hospital das Clinicas FMUSP
    São Paulo, 04266-010, Brazil
  • BR Trials - Ensaios Clinicos e Consultoria
    São Paulo, 05003-090, Brazil
  • Hospital das Clinicas FMUSP
    São Paulo, 05403-000, Brazil
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210011, China
  • Wuxi People's Hospital
    Wuxi, Jiangsu 214023, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • Zhongshan Hospital,Fudan University
    Shanghai, Shanghai 200032, China
  • West China Hospital, Sichuan University
    ChengDu, Sichuan 610041, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin 300052, China
  • Vseobecna fakultni nemocnice v Praze
    Praha 2, 12808, Czechia
  • Praglandia s.r.o
    Praha 5, 150 00, Czechia
  • Siteworks GmbH
    Hannover, Niedersachsen 30449, Germany
  • InnoDiab Forschung Gmbh
    Essen, Nordrhein-Westfalen 45136, Germany
  • Institut für Diabetesforschung GmbH Münster
    Münster, Nordrhein-Westfalen 48145, Germany
  • RED-Institut GmbH
    Oldenburg, Schleswig-Holstein 23758, Germany
  • Lungenpraxis Schleswig
    Schleswig, Schleswig-Holstein 24837, Germany
  • Advanced Sleep Research
    Berlin, 10117, Germany
  • Diabeteszentrum Hamburg West
    Hamburg, 22607, Germany
  • Koujunkai Daido Clinic
    Nagoya, Aichi 457-8511, Japan
  • Kirigaokatsuda Hospital
    Kitakyushu, Fukuoka 802-0052, Japan
  • RESM Respiratory and Sleep Medical Care Clinic
    Yokohama, Kanagawa 222-0033, Japan
  • Sakai City Medical Center
    Sakai, Osaka 593-8304, Japan
  • Fukuwa Clinic
    Chuo-ku, Tokyo 104-0031, Japan
  • Osaka Kaisei Hospital
    Osaka, 532-0003, Japan
  • RM Pharma Specialists
    Mexico City, Distrito Federal 03100, Mexico
  • Centro Especializado En Diabetes, Obesidad Y Prevencion De Enfermedades Cardiovasculares
    Mexico City, Distrito Federal 11650, Mexico
  • Private Practice - Dr. Arechavaleta Granell Maria del Rosario
    Guadalajara, Jalisco 44670, Mexico
  • Unidad de Investigación Clínica y Atención Médica HEPA
    Guadalajara, Jalisco 44670, Mexico
  • Servicios Integrales Nova de Monterrey S.A. de C.V.
    San Nicolas de los Garza, Nuevo León 66450, Mexico
  • Unidad Médica para la Salud Integral
    San Nicolás de los Garza, Nuevo León 66465, Mexico
  • Investigacion En Salud Y Metabolismo Sc
    Chihuahua, 31217, Mexico
  • Arké SMO S.A de C.V
    Veracruz, 91910, Mexico
  • Puerto Rico Medical Research Center
    Hato Rey, 00917, Puerto Rico
  • China Medical University Hospital
    Taichung, 404332, Taiwan
  • National Cheng Kung University Hospital
    Tainan, 704, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Mar 2024, 20 months.

Results were first posted in Apr 2025, 1 year 1 month after primary completion.

Of 27 phase 3 interventional studies under Sleep Apnea, Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 32. This study's 20 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2022
First posted
Jun 9, 2022
StartActual
Jun 21, 2022
Primary completionActual
Mar 12, 2024
CompletionActual
Mar 29, 2024
Results first posted
Apr 30, 2025
Last update
Apr 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05412004
Responsible party
Sponsor
First posted
Jun 9, 2022
Start date
Jun 21, 2022
Primary completion
Mar 12, 2024
Completion
Mar 29, 2024
Results posted
Apr 30, 2025
Last update
Apr 30, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion